Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
1 recherche sur le mot-clé 'Chronic Pain/complications/drug therapy'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Risk of exposure to prescription opioids in children and adolescents with autism spectrum disorder: A nationwide longitudinal study / Ju-Wei HSU in Autism Research, 15-11 (November 2022)
[article]
Titre : Risk of exposure to prescription opioids in children and adolescents with autism spectrum disorder: A nationwide longitudinal study Type de document : Texte imprimé et/ou numérique Auteurs : Ju-Wei HSU, Auteur ; Shih-Jen TSAI, Auteur ; Ya-Mei BAI, Auteur ; Kai-Lin HUANG, Auteur ; Tung-Ping SU, Auteur ; Tzeng-Ji CHEN, Auteur ; Mu-Hong CHEN, Auteur Article en page(s) : p.2192-2199 Langues : Anglais (eng) Mots-clés : Child Adolescent Humans Autism Spectrum Disorder/drug therapy Longitudinal Studies Analgesics, Opioid/adverse effects Chronic Pain/complications/drug therapy Prescriptions autism medical conditions mental disorders prescription opioids Index. décimale : PER Périodiques Résumé : Whether children and adolescents with autism spectrum disorder (ASD) are more likely to be exposed to prescription opioids than others remains unknown. The Taiwan National Health Insurance Research Database was employed, and 14,849 children and adolescents with ASD and 148,490 age- and sex-matched non-ASD controls were enrolled between 2001 and 2009 and followed up till the end of 2011. Those exposed to prescription opioids during the follow-up period were identified. Patients with ASD were more likely to be exposed to prescription opioids (hazard ratio [HR]: 4.95, 95% confidence interval [CI]: 4.50-5.45), including intravenous or intramuscular opioids (HR: 5.80, 95% CI: 5.23-6.43) and oral or transcutaneous opioids (HR: 2.32, 95% CI: 1.87-2.89), than were non-ASD controls. Furthermore, the ASD cohort had the increased likelihood of cumulative exposure of>14 days (HR: 6.19, 95% CI: 4.91-7.79) and>30 days (HR: 7.17, 95% CI: 5.19-9.90) to prescription opioids compared with the control cohort. ASD was a risk factor for exposure to prescription opioids. Close monitoring of prescription opioid use is necessary for at-risk children and adolescents with ASD, such as those having with or chronic pain. We found that patients with ASD were more likely to be exposed to prescription opioids, including intravenous or intramuscular opioids and oral or transcutaneous opioids, than were non-ASD controls. We suggest that close monitoring of prescription opioid use is necessary for at-risk children and adolescents with ASD, such as those having with or chronic pain. En ligne : http://dx.doi.org/10.1002/aur.2806 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=488
in Autism Research > 15-11 (November 2022) . - p.2192-2199[article] Risk of exposure to prescription opioids in children and adolescents with autism spectrum disorder: A nationwide longitudinal study [Texte imprimé et/ou numérique] / Ju-Wei HSU, Auteur ; Shih-Jen TSAI, Auteur ; Ya-Mei BAI, Auteur ; Kai-Lin HUANG, Auteur ; Tung-Ping SU, Auteur ; Tzeng-Ji CHEN, Auteur ; Mu-Hong CHEN, Auteur . - p.2192-2199.
Langues : Anglais (eng)
in Autism Research > 15-11 (November 2022) . - p.2192-2199
Mots-clés : Child Adolescent Humans Autism Spectrum Disorder/drug therapy Longitudinal Studies Analgesics, Opioid/adverse effects Chronic Pain/complications/drug therapy Prescriptions autism medical conditions mental disorders prescription opioids Index. décimale : PER Périodiques Résumé : Whether children and adolescents with autism spectrum disorder (ASD) are more likely to be exposed to prescription opioids than others remains unknown. The Taiwan National Health Insurance Research Database was employed, and 14,849 children and adolescents with ASD and 148,490 age- and sex-matched non-ASD controls were enrolled between 2001 and 2009 and followed up till the end of 2011. Those exposed to prescription opioids during the follow-up period were identified. Patients with ASD were more likely to be exposed to prescription opioids (hazard ratio [HR]: 4.95, 95% confidence interval [CI]: 4.50-5.45), including intravenous or intramuscular opioids (HR: 5.80, 95% CI: 5.23-6.43) and oral or transcutaneous opioids (HR: 2.32, 95% CI: 1.87-2.89), than were non-ASD controls. Furthermore, the ASD cohort had the increased likelihood of cumulative exposure of>14 days (HR: 6.19, 95% CI: 4.91-7.79) and>30 days (HR: 7.17, 95% CI: 5.19-9.90) to prescription opioids compared with the control cohort. ASD was a risk factor for exposure to prescription opioids. Close monitoring of prescription opioid use is necessary for at-risk children and adolescents with ASD, such as those having with or chronic pain. We found that patients with ASD were more likely to be exposed to prescription opioids, including intravenous or intramuscular opioids and oral or transcutaneous opioids, than were non-ASD controls. We suggest that close monitoring of prescription opioid use is necessary for at-risk children and adolescents with ASD, such as those having with or chronic pain. En ligne : http://dx.doi.org/10.1002/aur.2806 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=488